Work

The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2 (Small 39/2024)

Year: 2024

Type: article

Abstract: COVID-19 Antiviral The global need for next generation antivirals due to SARS-CoV-2 mutations led to interest in niclosamide, a broad spectrum antiviral. XAFTY is a niclosamide-inorganic nanohybrid drug proven for its broad-spectrum antiviral activity, overcoming niclosamide's low bioavailability. It has been confirmed in animal models to reduce SARS-CoV-2 viral load and prevent infection-induced lung inflammation, and its safety was confirmed in the clinical trials. More in article number 2305148, Geun-woo Jin, Jin-Ho Choy, and co-workers.

Source: Small

DOI: 10.1002/smll.202470291

Authors: Goeun Choi, N. Sanoj Rejinold, Huiyan Piao, Young Bae Ryu, Hyung‐Jun Kwon, In Chul Lee, Jeong In Seo, Hye Hyun Yoo, Geun‐woo Jin, Jin‐Ho Choy

Institutions: Dankook University, Korea Research Institute of Bioscience and Biotechnology, Hanyang University, Tokyo Institute of Technology

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4407374858

FWCI:

Cites:

Cited by:

Related to: 10